JOHN KIRKWOOD to Neoplasm Proteins
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Neoplasm Proteins.
Connection Strength
0.691
-
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep. 2019 03 01; 9(1):3309.
Score: 0.117
-
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
Score: 0.112
-
Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer. 2012 Aug 15; 131(4):874-84.
Score: 0.072
-
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
Score: 0.057
-
A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6796-806.
Score: 0.054
-
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol. 1987 Aug; 5(8):1247-55.
Score: 0.053
-
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15; 177(4):2717-27.
Score: 0.049
-
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2003 Mar; 9(3):947-54.
Score: 0.039
-
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med. 2002 Sep 02; 196(5):619-28.
Score: 0.037
-
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000 Jan 04; 97(1):400-5.
Score: 0.031
-
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
Score: 0.026
-
Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients. J Immunol. 2007 Dec 01; 179(11):7932-40.
Score: 0.013
-
Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma. J Invest Dermatol. 1985 May; 84(5):430-2.
Score: 0.011
-
Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes. Cancer Biol Ther. 2004 Jan; 3(1):110-20.
Score: 0.010
-
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004 Mar; 50(3):564-73.
Score: 0.010